Market Overview:
The global alpha-1 antitrypsin deficiency augmentation therapy market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to factors such as increasing prevalence of alpha-1 antitrypsin deficiency, rising awareness about the benefits of augmentation therapy and technological advancements in the field of alpha-1 antitrypsin deficiency augmentation therapy. However, high cost associated with treatment is likely to restrain the growth of this market during the forecast period. Based on type, the global alpha-1 antitrypsin deficiency augmentation therapy market has been segmented into glassia, aralast NP, prolastin C and others. Glassia held a dominant share in 2017 and is expected to maintain its dominance throughout the forecast period. This can be attributed to its high efficacy and safety profile coupled with increasing demand for it across regions. Aralast NP is anticipated to grow at a highest CAGR owing to growing preference for it over other therapies due to lower price point as compared Glassia and Prolastin C therapies . Based on application, hospitals accounted for majority share in 2017 and is anticipated retain its dominance throughout 2030 owing higher adoption rates across regions coupled with rising number of patients suffering from Alpha 1 Antitrypsin Deficiency (AATD).
Product Definition:
Alpha-1 Antitrypsin Deficiency Augmentation Therapy is a therapy used to increase the levels of Alpha-1 Antitrypsin in people with Alpha-1 Antitrypsin Deficiency. The therapy consists of weekly intravenous infusions of Alpha-1 Antitrypsin. The importance of this therapy is that it can help to prevent or reduce the amount of damage caused by Alpha-1 Antitrypsin Deficiency.
Glassia:
Glassia is a drug that increases the production of a protein called alpha-1 antitrypsin in the human body. The main function of this protein is to protect from conditions such as emphysema and bronchitis. Emphysema occurs when there is too much production of this protective protein, leading to lung damage. Bronchitis occurs when there is not enough production of this protective protein, which can lead to inflammation and infection in the lungs (and other parts).
Aralast NP:
Aralast NP is a prescription drug used to treat Alpha-1 Antitrypsin (AAT) deficiency. It works by increasing the level of AAT in the blood, which is not produced in adequate amounts due to a genetic mutation. The drug has been approved by both the U.S.
Application Insights:
The application segment is segregated into hospitals and specialty clinics. Hospitals held the largest share of the market in 2017 owing to availability of a large number of treatment centers at hospitals, which caters to a large patient base with alpha-1 antitrypsin deficiency augmenting therapy.
Moreover, there are several manufacturers providing product formulations that can be used for patients admitted in hospital settings which include nutrition support formula and dry powder inhaler. These factors are anticipated to drive the hospital segment over the forecast period.
Specialty clinics hold smaller share as compared with hospitals but have higher penetration rates due to advanced diagnosis & treatment facilities coupled with more extensive use of alpha-1 antitrypsin deficiency augmenting therapies by medical specialists at these clinics than by general physicians or family practitioners at their offices or private practices.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate of novel therapeutics are some factors responsible for its large share. Moreover, increasing prevalence of chronic diseases is also expected to drive the growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to untapped opportunities in this region coupled with rising disposable income levels especially in developing countries such as India & China.
Growth Factors:
- Increasing incidence of Alpha-1 Antitrypsin Deficiency (AATD)
- Growing awareness about AATD and its treatment options
- Rising demand for better and more effective therapies for AATD
- Technological advancements in the field of augmentation therapy for AATD 5. Availability of government funding and support for research on augmentation therapy for AATD
Scope Of The Report
Report Attributes
Report Details
Report Title
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Research Report
By Type
Glassia, Aralast NP, Prolastin C, Others
By Application
Hospitals, Specialty Clinics
By Companies
Grifols, CSL, Baxter, Kamada, Takeda, Abeona
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report Segments:
The global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market is segmented on the basis of:
Types
Glassia, Aralast NP, Prolastin C, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Grifols
- CSL
- Baxter
- Kamada
- Takeda
- Abeona
Highlights of The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Glassia
- Aralast NP
- Prolastin C
- Others
- By Application:
- Hospitals
- Specialty Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alpha-1 antitrypsin deficiency augmentation therapy is a treatment for people who have alpha-1 antitrypsin deficiency. This therapy helps to increase the levels of alpha-1 antitrypsin in the blood. This can help to protect against diseases that are caused by low levels of alpha-1 antitrypsin, such as emphysema and lung cancer.
Some of the major players in the alpha-1 antitrypsin deficiency augmentation therapy market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona.
The alpha-1 antitrypsin deficiency augmentation therapy market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size & Forecast, 2018-2028
4.5.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Y-o-Y Growth
4.5.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Absolute $ Opportunity
Chapter 5 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type
5.2.1 Glassia
5.2.2 Aralast NP
5.2.3 Prolastin C
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Analysis and Forecast
9.1 Introduction
9.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type
9.6.1 Glassia
9.6.2 Aralast NP
9.6.3 Prolastin C
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialty Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type
10.6.1 Glassia
10.6.2 Aralast NP
10.6.3 Prolastin C
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialty Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type
11.6.1 Glassia
11.6.2 Aralast NP
11.6.3 Prolastin C
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialty Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type
12.6.1 Glassia
12.6.2 Aralast NP
12.6.3 Prolastin C
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialty Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Alpha-1 Antitrypsin Deficiency Augmentation Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type
13.6.1 Glassia
13.6.2 Aralast NP
13.6.3 Prolastin C
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialty Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Competitive Dashboard
14.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Grifols
14.3.2 CSL
14.3.3 Baxter
14.3.4 Kamada
14.3.5 Takeda
14.3.6 Abeona
